Allogeneic HSCT for Symptomatic Female X-linked Chronic Granulomatous Disease Carriers

Area of Science:

• Immunology
• Genetics
• Hematology

Background:

• X-linked chronic granulomatous disease (XL-CGD) is an inherited phagocyte disorder affecting superoxide production.
• XL-CGD carriers were thought to be asymptomatic, but some exhibit morbidity due to skewed lyonization and impaired oxidative burst.
• Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for XL-CGD but rarely used in symptomatic carriers.

Purpose of the Study:

• To evaluate the outcomes of allogeneic HSCT in symptomatic female XL-CGD carriers.
• To assess the efficacy of HSCT in resolving infections, inflammation, and autoimmunity in this patient subgroup.

Main Methods:

• Retrospective international survey of seven symptomatic XL-CGD carriers (aged 1-56 years) who underwent HSCT across four centers.
• Data collected on indications for HSCT, transplant complications, engraftment, oxidative burst restoration, and clinical outcomes.

Main Results:

• Two of seven patients died from transplant-related complications.
• Surviving patients showed restored neutrophil oxidative burst, reduced infections, and decreased inflammatory symptoms.
• HSCT led to resolution of colitis and autoimmunity, with cessation of immunosuppressive therapy in survivors.

Conclusions:

• Allogeneic HSCT can be a curative option for symptomatic XL-CGD carriers, effectively addressing phagocyte defects and associated severe symptoms.
• While HSCT offers significant clinical improvement, it carries risks of transplant-related complications that must be carefully managed.